ANG-3070, is a highly selective, oral small molecule tyrosine kinase receptor inhibitor developed internally as a potential treatment for chronic fibrotic diseases, particularly in the kidney and lung. ANG-3070 is an investigational product and is not approved by any regulatory authority.
The initial focus for our ROCK2 program is expected to be on fibrotic indications such as chronic kidney disease and IPF. Given the heterogeneity of these diseases, we believe development of this program will benefit from our precision medicine approach and use of established clinical biomarkers.
We are leveraging our extensive experience in developing cytochrome P450 modulators to develop compounds with improved specificity for CYP11B2 relative to CYP11B1. In non-human primate models, one of our lead test compounds reduced aldosterone production following an ACTH challenge while having a minimal impact on cortisol production.